fluocinolone acetonide intravitreal implant

Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
Real-world experience: Positive DME treatment outcomes observed with FAc implant at UK centreDr Mushtaq discusses one centre’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg. The implant demonstrated favourable outcomes and good patient acceptance.
Real-world experience: Case study shows maintained benefits with FAc in DME patientIn the case study discussed in this article, a patient who was treated for DME with a fluocinolone acetonide intravitreal implant reported improved vision-related quality of life and the ability to perform daily routines without problems. These benefits persisted 12-months after treatment.
Real-world setting proving positive for intravitreal implant for DMEOne center’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg demonstrates favorable outcomes and good patient acceptance.
Alimera resubmits Iluvien NDA to FDAAlimera Sciences has resubmitted its New Drug Application (NDA) for its fluocinolone acetonide intravitreal implant (Iluvien) to the FDA.
Retina drug therapies ever evolvingMedical advances run gamut from AMD to symptomatic vitreomacular adhesion
French commission favors reimbursement of IluvienThe Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.
UK’s NICE panel issues positive appraisal for IluvienThe Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued a positive Appraisal Consultation Document (ACD) for the 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of pseudophakic patients with chronic diabetic macular edema (DME) and who are unresponsive to existing therapies.